BioMarin Pharmaceuticals Inc (BMRN)
What changed in recent filings
- GALAFOLD segment 0% → 11%Jun 30, 2025 → Jun 30, 2026
- Institutions — 3 new · 2 added13F · as of end of 2026 Q2
- Debt-to-equity 0.2x → 0.7xMar 31, 2026 → Jun 30, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding BioMarin Pharmaceuticals Inc
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 3 → 2026 Q2: 6 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold BioMarin Pharmaceuticals Inc
Institutions we track that reported holding this stock in their most recent 13F.
- Dodge & Cox0.44% of portfolio · since 2019 Q4
- Bridgewater Associates0.06% of portfolio · since 2021 Q1
- Viking Global Investors1.24% of portfolio · since 2021 Q4
- Caisse de depot (Quebec)0.10% of portfolio · held as of 2026 Q2 or earlier
- Blackstoneunder 0.01% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management0.48% of portfolio · held as of 2026 Q2 or earlier
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
BioMarin. A biotech specialized in drugs for rare enzyme-deficiency diseases. It generates stable income via high drug prices and few competitors.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
BioMarin Pharmaceuticals Inc is classified under the Biotech & Health sector. See peers below.
BioMarin Pharmaceuticals Inc key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
BioMarin Pharmaceuticals Inc vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
BMRN segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
BMRN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
BMRN FAQ
What is BioMarin Pharmaceuticals Inc (BMRN)?
BioMarin. A biotech specialized in drugs for rare enzyme-deficiency diseases. It generates stable income via high drug prices and few competitors.
What sector is BioMarin Pharmaceuticals Inc in?
BioMarin Pharmaceuticals Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are BioMarin Pharmaceuticals Inc's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 11.2%, Operating margin 11.2%, Net margin 2.1%, ROE 5.7%, Debt-to-equity 0.66x. Definitions and interpretation are available on Stocklore.
Where can I analyze BioMarin Pharmaceuticals Inc (BMRN) stock?
On Stocklore you can see BMRN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.